Clinical Trial

Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Recruiting
View on ClinicalTrials.gov →
Summary
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-11-26; most recent amendment 2026-01-15.
Status change: Not Yet Recruiting → Recruiting 2026-01-15
Trial Details
NCT Number NCT06712459
Lead Sponsor International Extranodal Lymphoma Study Group (IELSG)
Conditions Transformed Splenic Marginal Zone Lymphoma
Enrollment 100 participants
Start Date 2025-10-13
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-01-16